Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | G protein-coupled receptor class C group 6 member A |
| Gene Name | GPRC6A |
| Uniprot | Q5T6X5 (Human); Q8K4Z6 (Mouse) |
| Synonym | GPCR; bA86F4.3; G-protein coupled receptor family C group 6 member A; G protein-coupled receptor, family C, group 6, member A; G-protein coupled receptor GPCR33; predicted with SOSUI analysis; seven transmembrane helix receptor |
| Background | GPRC6A is a member of the family C G protein-coupled receptors, which are characterized by the presence of a seven-transmembrane domain and an unusually long amino-terminal domain (ATD). This receptor was initially deorphanized by infusion of its large N-terminal domain to the heptahelical and C-terminal region of the related goldfish 5.24 receptor. Cell signaling studies suggest that the receptor couples primarily via the Gαq/11 pathway to increase inositol phosphate production and mobilize intracellular calcium. Besides, it may also increase cyclic AMP and/or phosphorylation of extracellular signal-regulated kinase-1/2. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX223 | NativeExtract™ Human GPRC6A Membrane Protein (Full length, Super Nanodisc) | HEK293 cells | Full length | Native Nanodisc |
| Please for more products or customization | ||||
L**a: Turnaround time and technical support streamlined our drug discovery pipeline.
08/Dec/2023
We provide tailored solutions to meet your specific requirements. Please for more services.
Creative Biolabs offers targeted genome editing services. Precision genome-editing technologies enable the stable integration of therapeutic constructs into the GPRC6A locus. For instance, homology-directed repair templates can be engineered to introduce gain-of-function mutations or restore wild-type receptor activity in disease models characterized by GPRC6A dysregulation. Creative Biolabs' proprietary screening platforms validate RNA efficiency and minimize off-target effects, ensuring high-fidelity edits tailored to metabolic or osteogenic disorders where GPRC6A signaling is pivotal.
Creative Biolabs offers AAV-mediated GPRC6A overexpression services. Adeno-associated virus (AAV) vectors engineered with tissue-specific promoters can deliver GPRC6A transgenes to bone marrow stromal cells, enhancing receptor expression to amplify osteoblast differentiation. Preclinical studies demonstrate that localized AAV delivery rescues bone mineral density in rodent models of age-related osteoporosis by augmenting GPRC6A's responsiveness to extracellular ligands, such as osteocalcin. Creative Biolabs' expertise in capsid optimization ensures selective transduction of skeletal tissues, minimizing off-target transgene expression.
Creative Biolabs offers epigenetic modulation services. mRNA-lipid nanoparticles (LNPs) encoding GPRC6A-targeted transcriptional activators transiently upregulate receptor expression in hepatocytes or pancreatic β-cells, potentiating insulin sensitivity. Unlike viral vectors, mRNA-LNPs offer transient, dose-controllable modulation—ideal for acute metabolic syndromes. Creative Biolabs' endosome escape-enhancing formulations maximize mRNA delivery efficiency, as validated in in vitro models of hepatic steatosis.
Creative Biolabs offers comprehensive and innovative services to drive the development of GPRC6A cell therapy. Please for more services.
Creative Biolabs offers CAR-T cell engineering services. Chimeric antigen receptor (CAR)-T cells engineered to recognize GPRC6A-overexpressing tumor cells exhibit potent cytotoxicity in preclinical models of prostate and breast cancers. By fusing extracellular ligand-binding domains to intracellular T-cell activation motifs, these CAR-T constructs selectively eliminate malignant cells while sparing healthy tissues. Creative Biolabs' in silico epitope mapping and ex vivo functional assays optimize receptor-binding affinity, mitigating on-target, off-tumor toxicity risks.
Creative Biolabs offers MSC-mediated GPRC6A antagonism development services. Genetically modified MSCs secreting GPRC6A-neutralizing antibodies locally suppress receptor hyperactivation in inflammatory microenvironments, such as rheumatoid arthritis. Encapsulation within biocompatible scaffolds ensures sustained antibody release, dampening cytokine-driven joint destruction. Creative Biolabs' 3D bioprinting technologies enable precise spatial distribution of MSC-laden hydrogels, enhancing therapeutic retention at disease sites.
Creative Biolabs offers macrophage reprogramming via GPRC6A-specific shRNA delivery services. Lentiviral vectors delivering short hairpin RNAs (shRNAs) against GPRC6A reprogram tumor-associated macrophages (TAMs) from a pro-tumoral M2 to an anti-tumoral M1 phenotype. In glioblastoma models, this shift enhances phagocytic activity and synergizes with checkpoint inhibitors. Creative Biolabs' lentiviral tropism optimization ensures high transduction rates in primary macrophages, a critical step for clinical translation.
The intricate biology of GPRC6A demands a multidisciplinary approach, blending cutting-edge gene editing, viral vector engineering, and cell-based modalities. Creative Biolabs' end-to-end solutions—from target validation to preclinical efficacy testing—empower researchers to overcome technical bottlenecks and accelerate timelines. to explore how our bespoke platforms can refine your GPRC6A-focused therapeutic strategy, ensuring precision, scalability, and regulatory compliance.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
